US
Patent Prosecution
Patent Strategy & Management
| Patent Strategy and Management-Highly recommended |
|---|
| Choate Hall & Stewart |
| Cooley |
| Fenwick & West |
| Finnegan Henderson Farabow Garrett & Dunner |
| Fish & Richardson |
| Goodwin Procter |
| Knobbe Martens |
| Marshall Gerstein & Borun |
| Morrison & Foerster |
| Wilson Sonsini Goodrich & Rosati |
| Wolf Greenfield & Sacks |
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Gagala, Bruce | Intellectual Property | General Patent Litigation, Patent Prosecution, Hatch-Waxman Patent Litigation | Chicago |
| Hasan, Salim | Intellectual Property | General Patent Litigation, Patent Strategy & Management | Chicago |
| Kilyk, John | Intellectual Property | General Patent Litigation, Patent Prosecution, Patent Strategy & Management, Hatch-Waxman Patent Litigation | Chicago |
| Sklar, Steven | Intellectual Property | Patent Strategy & Management, Hatch-Waxman Patent Litigation | Chicago |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Intellectual Property
Leydig Voit & Mayer
IP firm Leydig Voit & Mayer is notable for its representation of life sciences clients in patent prosecution and strategy, and continues to show involvement in noteworthy patent litigations. The firm expanded its footprint this year in Colorado with the strategic hiring of several Lathrop Gage life sciences IP attorneys.
Bruce Gagala and John Kilyk are two of the firm's leading members in the life sciences practice, who each offer deep experience in patent strategy and litigation. The two attorneys were both involved in a significant biologics dispute for Samsung Bioepis against Janssen, resulting in the client moving forward with its biosimilar version of the blockbuster drug Remicade. Salim Hasan has more than 25 years of experience in IP law, which encompasses both patent strategy and IP litigation. His knowledge of patent issues extends to global jurisdictions.
Steve Sklar is new to the life sciences stars list for his work in Hatch-Waxman litigations for generic clients. He was recently active for Aurobindo in a Hatch-Waxman dispute against Amgen.